CLPP and glioma: We previously reported that the atypical dopamine receptor 2/3 antagonist and caseinolytic protease P (ClpP) activator ONC201 (16), now in clinical trials against pediatric glioma, also prevented radiation-induced phenotype conversion of non-stem glioma cells into glioma stem cells and prolonged median survival in mouse models of GBM (5).